A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

Trial Profile

A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2018

At a glance

  • Drugs Glecaprevir/pibrentasvir (Primary)
  • Indications Hepatitis C; Liver cirrhosis
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 22 Jun 2018 Planned number of patients changed from 270 to 330.
    • 22 Jun 2018 Planned End Date changed from 10 Dec 2018 to 2 Nov 2019.
    • 22 Jun 2018 Planned primary completion date changed from 24 May 2018 to 18 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top